DelveInsight’s “Congenital Adrenal Hyperplasia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Congenital Adrenal Hyperplasia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Congenital Adrenal Hyperplasia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Congenital Adrenal Hyperplasia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Congenital Adrenal Hyperplasia: An Overview
Congenital adrenal hyperplasia (CAH) is a group of rare inherited autosomal recessive disorders characterized by a deficiency of one of the enzymes needed to make specific hormones. CAH affects the adrenal glands located at the top of each kidney.
The most common cause of CAH is the absence of the enzyme 21-hydroxylase. Different mutations in the gene are responsible for 21-hydroxylase, which results in different levels of the enzyme, producing a spectrum of effects. 21-hydroxylase deficiency is broken down further into two subcategories: Classical CAH, which can be subdivided into the Salt-Losing (SL) form the Simple-Virilizing (SV) form, and Non-Classical CAH. Classical CAH is by far the more severe form and can result in adrenal crisis and death if not detected and treated. Non-classical CAH is milder, and may or may not present symptoms
Clinicians depend on consistent validated hormone determinations to confirm the diagnosis of the disorder of steroidogenesis. The initial screening test is done by measuring serum 17OHP to screen for 21-hydroxylase deficiency. Newborn screening is recommended for CAH diagnosis however, non-classic CAH is frequently not detected in the newborn test and therefore, may not be diagnosed until childhood or early adulthood when the patient first starts showing symptoms.
Congenital Adrenal Hyperplasia Market Key Facts
-
The Congenital Adrenal Hyperplasia diagnosed prevalence in the 7MM countries was estimated to be close to 73,000 cases in 2021.
-
According to a study by Witchel et al, (2017), the incidence of the classic forms is reported to be in the range from 1:5000 to 1:15,000 and varies among ethnic/racial backgrounds. Additionally, the prevalence of 21-OHD is lower among African Americans than among Caucasians in the United States.
-
According to the National Organization for Rare Disorders (NORD), (n.d.), the most common form of CAH affects approximately 1/10,000–1/15,000 people in the United States and Europe.
-
Some of the key companies in the Congenital Adrenal Hyperplasia (CAH) Market include Neurocrine Biosciences, Diurnal Limited, Spruce Biosciences, Adrenas Therapeutics, Millendo Therapeutics, and others.
Congenital Adrenal Hyperplasia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Congenital Adrenal Hyperplasia pipeline therapies. It also thoroughly assesses the Congenital Adrenal Hyperplasia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Congenital Adrenal Hyperplasia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Congenital Adrenal Hyperplasia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Congenital Adrenal Hyperplasia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Congenital Adrenal Hyperplasia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Congenital Adrenal Hyperplasia Epidemiology, Segmented as –
-
Total Prevalent Cases of Congenital Adrenal Hyperplasia in the 7MM [2019–2032]
-
Diagnosed Prevalent Cases of Classic and Non-classic Congenital Adrenal Hyperplasia in the 7MM [2019–2032]
-
Total Diagnosed Cases of Congenital Adrenal Hyperplasia in the 7MM [2019–2032]
Congenital Adrenal Hyperplasia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Congenital Adrenal Hyperplasia market or expected to be launched during the study period. The analysis covers the Congenital Adrenal Hyperplasia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Congenital Adrenal Hyperplasia drugs based on their sale and market share.
The report also covers the Congenital Adrenal Hyperplasia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Congenital Adrenal Hyperplasia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Congenital Adrenal Hyperplasia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/congenital-adrenal-hyperplasia-market
Congenital Adrenal Hyperplasia Therapeutics Analysis
Currently, there is no cure for Congenital Adrenal Hyperplasia. However, treatments are available to address some of the associated symptoms Patients benefit from taking hormone replacement medications, which work to increase levels of deficient hormones and suppress the overproduction of male hormones. The available therapeutics treatment options in the Congenital Adrenal Hyperplasia Landscape focus on reducing the excess adrenal androgen production and replacing the deficient hormones, namely cortisol, and aldosterone.
Several major pharma and biotech companies are developing therapies for Congenital Adrenal Hyperplasia. Currently, Diurnal Group plc is leading the therapeutics market with its Congenital Adrenal Hyperplasia drug candidates in the most advanced stage of clinical development. Novel treatment options aim to reduce glucocorticoid exposure, improve excess hormone control (e.g. Tildacerfont), and mimic physiological hormone patterns (e.g. Chronocort).
Congenital Adrenal Hyperplasia Companies Actively Working in the Therapeutics Market Include
-
Neurocrine Biosciences
-
Diurnal Limited
-
Spruce Biosciences
-
Adrenas Therapeutics
-
Millendo Therapeutics
-
Crinetics Pharmaceuticals
And Many Others
Emerging and Marketed Congenital Adrenal Hyperplasia Therapies Covered in the Report Include:
-
Chronocort: Diurnal Group plc
-
NBI-74788: Neurocrine Biosciences
-
Tildacerfont: Spruce Biosciences
-
BBP-631: Adrenas Therapeutics Inc
-
Efmody: Diurnal Group plc
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/congenital-adrenal-hyperplasia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Congenital Adrenal Hyperplasia Competitive Intelligence Analysis
4. Congenital Adrenal Hyperplasia Market Overview at a Glance
5. Congenital Adrenal Hyperplasia Disease Background and Overview
6. Congenital Adrenal Hyperplasia Patient Journey
7. Congenital Adrenal Hyperplasia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Congenital Adrenal Hyperplasia Treatment Algorithm, Current Treatment, and Medical Practices
9. Congenital Adrenal Hyperplasia Unmet Needs
10. Key Endpoints of Congenital Adrenal Hyperplasia Treatment
11. Congenital Adrenal Hyperplasia Marketed Therapies
12. Congenital Adrenal Hyperplasia Emerging Drugs and Latest Therapeutic Advances
13. Congenital Adrenal Hyperplasia Seven Major Market Analysis
14. Attribute Analysis
15. Congenital Adrenal Hyperplasia Market Outlook (In US, EU5, and Japan)
16. Congenital Adrenal Hyperplasia Companies Active in the Market
17. Congenital Adrenal Hyperplasia Access and Reimbursement Overview
18. KOL Views on the Congenital Adrenal Hyperplasia Market
19. Congenital Adrenal Hyperplasia Market Drivers
20. Congenital Adrenal Hyperplasia Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/congenital-adrenal-hyperplasia-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
“Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Pancreatic Cancer market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Pancreatic Cancer market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices